# Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers

> **NCT02195804** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 42 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ranitidine hydrochloride ODT
- **DRUG:** Ranitidine hydrochloride ODT RM
- **DRUG:** Ranitidine hydrochloride

## Key facts

- **NCT ID:** NCT02195804
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195804, "Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02195804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*